MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction. Its product pipeline also comprises MN-221 (bedoradrine), a selective -adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNOV
Previous Symbol
CUSIPN/A
Phone858-373-1500
Debt
Debt-to-Equity RatioN/A
Current Ratio34.89
Quick Ratio34.89
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.07 per share
Price / Book8.42
Profitability
EPS (Most Recent Fiscal Year)($0.32)
Net Income$-11,160,000.00
Net MarginsN/A
Return on Equity-24.40%
Return on Assets-23.07%
Miscellaneous
Employees9
Outstanding Shares41,880,000
Market Cap$371.07 million
OptionableOptionable
MediciNova (NASDAQ:MNOV) Frequently Asked Questions
What is MediciNova's stock symbol?
MediciNova trades on the NASDAQ under the ticker symbol "MNOV."
How were MediciNova's earnings last quarter?
MediciNova, Inc. (NASDAQ:MNOV) posted its earnings results on Thursday, October, 29th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.04. View MediciNova's Earnings History.
What price target have analysts set for MNOV?
1 equities research analysts have issued twelve-month price targets for MediciNova's stock. Their forecasts range from $22.00 to $22.00. On average, they anticipate MediciNova's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 144.2% from the stock's current price. View Analyst Price Targets for MediciNova.
What is the consensus analysts' recommendation for MediciNova?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MediciNova.
Has MediciNova been receiving favorable news coverage?
Media stories about MNOV stock have trended negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. MediciNova earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the immediate future.
Who are some of MediciNova's key competitors?
Some companies that are related to MediciNova include Theravance Biopharma (TBPH), Wave Life Sciences (WVE), Enanta Pharmaceuticals (ENTA), The Medicines (MDCO), Cambrex (CBM), Vanda Pharmaceuticals (VNDA), Zai Lab (ZLAB), Tricida (TCDA), Aimmune Therapeutics (AIMT), Phibro Animal Health (PAHC), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Nabriva Therapeutics (NBRV), Esperion Therapeutics (ESPR) and Portola Pharmaceuticals (PTLA).
Who are MediciNova's key executives?
MediciNova's management team includes the folowing people:
- Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 68)
- Mr. Masatsune Okajima, Head of Japanese Office & VP (Age 50)
- Dr. Kazuko Matsuda M.D., Ph.D., MPH, Chief Medical Officer (Age 52)
- Mr. Geoffrey G. O'Brien, VP & Exec. Officer (Age 49)
- Ms. Carla Reyes, Chief Financial Officer (Age 46)
Who are MediciNova's major shareholders?
MediciNova's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.75%), Vanguard Group Inc. (3.78%), Vanguard Group Inc (3.78%), FMR LLC (0.99%), Bridgeway Capital Management Inc. (0.32%) and TIAA CREF Investment Management LLC (0.18%). Company insiders that own MediciNova stock include Yoshio Ishizaka and Yutaka Kobayashi. View Institutional Ownership Trends for MediciNova.
Which major investors are selling MediciNova stock?
Which major investors are buying MediciNova stock?
MNOV stock was purchased by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., BlackRock Inc., Vanguard Group Inc, Vanguard Group Inc., Alps Advisors Inc., Alliancebernstein L.P., MetLife Investment Advisors LLC and Jane Street Group LLC. Company insiders that have bought MediciNova stock in the last two years include Yoshio Ishizaka and Yutaka Kobayashi. View Insider Buying and Selling for MediciNova.
How do I buy shares of MediciNova?
Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MediciNova's stock price today?
One share of MNOV stock can currently be purchased for approximately $9.01.
How big of a company is MediciNova?
MediciNova has a market capitalization of $371.07 million. The biopharmaceutical company earns $-11,160,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. MediciNova employs 9 workers across the globe.
What is MediciNova's official website?
How can I contact MediciNova?
MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]
MarketBeat Community Rating for MediciNova (NASDAQ MNOV)
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe MNOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
